Experimental cancer drug tested in rare tumors, but trial stopped early
NCT ID NCT03165721
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested the drug guadecitabine (SGI-110) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, and HLRCC-related kidney cancer that had not responded to other treatments. Participants received daily injections for 5 days every 28 days. The study was terminated early after enrolling only 9 people, so it is unclear if the drug is effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Guadecitabine (SGI-110)
- What this could lead to
- If it works, this could point toward a treatment option for certain rare cancers that have not responded to other therapies.
- What could go wrong
- This trial was terminated early with only 9 participants, so results are very limited. The drug may not shrink tumors or may cause side effects that outweigh benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a radioactive 'Smart Bomb' take down resistant childhood cancers?
- A simple blood draw may spot kidney cancer early
- Can a Brain-Cancer drug take on a stubborn stomach tumor?
- Can a radioated molecule shrink untreatable neuroblastoma?
- New drug aims to shrink rare adrenal tumors